Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Average Price Target of $23.42

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has earned a consensus recommendation of “Reduce” from the eleven analysts that are presently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a sell recommendation and seven have given a hold recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $23.42.

Several equities analysts recently issued reports on the company. Sanford C. Bernstein lifted their price objective on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a report on Thursday, August 6th. Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 15th. Berenberg Bank set a $24.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 29th. Finally, Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mather Group LLC. boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 838.0% during the 3rd quarter. Mather Group LLC. now owns 1,407 shares of the company’s stock worth $31,000 after purchasing an additional 1,257 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 39.1% during the third quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company’s stock worth $43,000 after purchasing an additional 538 shares during the last quarter. Allworth Financial LP grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the second quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock valued at $80,000 after purchasing an additional 850 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter valued at $91,000. Finally, EverSource Wealth Advisors LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 50.3% in the first quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock valued at $93,000 after purchasing an additional 1,383 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.3%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $22.75 on Tuesday. The company has a 50-day moving average of $22.48 and a two-hundred day moving average of $22.89. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.02 and a 12-month high of $27.40. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market cap of $12.22 billion, a PE ratio of 11.78, a price-to-earnings-growth ratio of 5.29 and a beta of 0.74.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.62 by $0.04. The business had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. On average, research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current fiscal year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.